A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT-P2)

I1F-MC-RHBE -

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Psoriatic Arthritis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
363
Trial Dates
Dec 31, 2014 - Jun 26, 2019
How long will I be in the trial?
Your participation could last up to 3 years and include 24 visits (plus additional follow up visits) to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.